ResearcherInstitute of Cancer ResearchActive in the last 2 years

Linxiang Lan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8409-4336; OpenAlex author ID A5070418482. Sources: OpenAlex.

Their work

Papers: 5 (first author 1, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 12

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: 2 papers · 2026: 2 papers

Papers 5

NKG2A-HLA-E and TIM3-galectin 9 pathways promote immune inhibition and represent therapeutic vulnerabilities in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00262-026-04479-9 ↗
A Jagged1-regulated hybrid-EMT state identifies pancreatic cancer stem cells. Co-author DOI 10.1016/j.celrep.2025.116909 ↗
Emerging insights into lineage plasticity in pancreatic cancer initiation, progression, and therapy resistance. Last author DOI 10.1016/j.devcel.2025.07.002 ↗
SPP1 is required for maintaining mesenchymal cell fate in pancreatic cancer. First author DOI 10.1038/s41586-025-09574-y ↗
GREM1 is required to maintain cellular heterogeneity in pancreatic cancer. Co-author DOI 10.1038/s41586-022-04888-7 ↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Axel Behrens · 4 shared papers, 2022–2026 · strength 0.96
Huafu Li · 3 shared papers, 2022–2026 · strength 0.59
Xintong Zhang · 1 shared paper, 2025 · strength 0.37
- Paper Emerging insights into lineage plasticity in pancreatic cancer initiation, progression, and therapy resistance. DOI 10.1016/j.devcel.2025.07.002 ↗
Jessica Kristine Nelson · 2 shared papers, 2022–2025 · strength 0.31
- Paper SPP1 is required for maintaining mesenchymal cell fate in pancreatic cancer. DOI 10.1038/s41586-025-09574-y ↗
- Paper GREM1 is required to maintain cellular heterogeneity in pancreatic cancer. DOI 10.1038/s41586-022-04888-7 ↗
Anguraj Sadanandam · 2 shared papers, 2022–2025 · strength 0.31
- Paper SPP1 is required for maintaining mesenchymal cell fate in pancreatic cancer. DOI 10.1038/s41586-025-09574-y ↗
- Paper GREM1 is required to maintain cellular heterogeneity in pancreatic cancer. DOI 10.1038/s41586-022-04888-7 ↗
Junzong Chen · 1 shared paper, 2026 · strength 0.23
- Paper NKG2A-HLA-E and TIM3-galectin 9 pathways promote immune inhibition and represent therapeutic vulnerabilities in pancrea… DOI 10.1007/s00262-026-04479-9 ↗
Youwen Fan · 1 shared paper, 2026 · strength 0.23
- Paper NKG2A-HLA-E and TIM3-galectin 9 pathways promote immune inhibition and represent therapeutic vulnerabilities in pancrea… DOI 10.1007/s00262-026-04479-9 ↗
Guoying Zhou · 1 shared paper, 2026 · strength 0.23
- Paper NKG2A-HLA-E and TIM3-galectin 9 pathways promote immune inhibition and represent therapeutic vulnerabilities in pancrea… DOI 10.1007/s00262-026-04479-9 ↗
Yuxin Lin · 1 shared paper, 2026 · strength 0.23
- Paper NKG2A-HLA-E and TIM3-galectin 9 pathways promote immune inhibition and represent therapeutic vulnerabilities in pancrea… DOI 10.1007/s00262-026-04479-9 ↗
Tingzhuang Yi · 1 shared paper, 2025 · strength 0.19
- Paper SPP1 is required for maintaining mesenchymal cell fate in pancreatic cancer. DOI 10.1038/s41586-025-09574-y ↗
Theodore Evan · 1 shared paper, 2022 · strength 0.12
- Paper GREM1 is required to maintain cellular heterogeneity in pancreatic cancer. DOI 10.1038/s41586-022-04888-7 ↗
Yoh Zen · 1 shared paper, 2022 · strength 0.12
- Paper GREM1 is required to maintain cellular heterogeneity in pancreatic cancer. DOI 10.1038/s41586-022-04888-7 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.